Lipid conjugation of TLR7 agonist Resiquimod ensures co‐delivery with the liposomal Cationic Adjuvant Formulation 01 (CAF01) but does not enhance immunopotentiation compared to non‐conjugated Resiquimod+CAF01

ABSTRACT Pattern recognition receptors, including the Toll‐like receptors (TLRs), are important in the induction and activation of two critical arms of the host defence to pathogens and microorganisms: the rapid innate immune response (as characterised by the production of Th1 promoting cytokines and type 1 interferons) and the adaptive immune response. Through this activation, ligands and agonists of TLRs can enhance immunotherapeutic efficacy. Resiquimod is a small (water‐soluble) agonist of the endosome‐located Toll‐like receptors 7 and 8 (TLR7/8). However due to its molecular attributes it rapidly distributes throughout the body after injection. To circumvent this, these TLR agonists can be incorporated within delivery systems, such as liposomes, to promote the co‐delivery of both antigen and agonists to antigen presenting cells. In this present study, resiquimod has been chemically conjugated to a lipid to form a lipid‐TLR7/8 agonist conjugate which can be incorporated within immunogenic cationic liposomes composed of dimethyldioctadecylammonium bromide (DDA) and the immunostimulatory glycolipid trehalose 6,6′ – dibehenate (TDB). This DDA:TDB‐TLR7/8 formulation offers similar vesicle characteristics to DDA:TDB (size and charge) and offers high retention of both resiquimod and the electrostatically adsorbed TB subunit antigen Ag85B‐ESAT6‐Rv2660c (H56). Following immunisation through the intramuscular (i.m.) route, these cationic DDA:TDB‐TLR7/8 liposomes form a vaccine depot at the injection site. However, immunisation studies have shown that this biodistribution does not translate into notably increased antibody nor Th1 responses at the spleen and draining popliteal lymph node compared to DDA:TDB liposomes. This work demonstrates that the conjugation of TLR7/8 agonists to cationic liposomes can promote co‐delivery but the immune responses stimulated do not merit the added complexity considerations of the formulation. HIGHLIGHTSResiquimod is a small water‐soluble agonist of Toll‐like receptors 7 and 8.A lipid conjugate of resiquimod was synthesised using a two‐step process.The lipid‐resiquimod conjugate was incorporated into a liposomal adjuvant.Co‐delivery of antigen, TLR and liposomal adjuvant was achieved.This co‐delivery did not notably enhance the already strong adjuvant action of the cationic liposomes.

[1]  H. Liao,et al.  Toll-Like Receptor 7/8 (TLR7/8) and TLR9 Agonists Cooperate To Enhance HIV-1 Envelope Antibody Responses in Rhesus Macaques , 2014, Journal of Virology.

[2]  Yvonne Perrie,et al.  The vesicle size of DDA:TDB liposomal adjuvants plays a role in the cell-mediated immune response but has no significant effect on antibody production. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[3]  Yvonne Perrie,et al.  A cationic vaccine adjuvant based on a saturated quaternary ammonium lipid have different in vivo distribution kinetics and display a distinct CD4 T cell-inducing capacity compared to its unsaturated analog. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[4]  E. Sandström,et al.  Topical delivery of imiquimod to a mouse model as a novel adjuvant for human immunodeficiency virus (HIV) DNA. , 2004, Vaccine.

[5]  E. De Gregorio,et al.  MF59 and Pam3CSK4 Boost Adaptive Responses to Influenza Subunit Vaccine through an IFN Type I-Independent Mechanism of Action , 2012, The Journal of Immunology.

[6]  R. Rappuoli,et al.  Vaccine composition formulated with a novel TLR7-dependent adjuvant induces high and broad protection against Staphylococcus aureus , 2015, Proceedings of the National Academy of Sciences.

[7]  Hailing Lu,et al.  The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system , 2011, Expert review of clinical pharmacology.

[8]  Yvonne Perrie,et al.  Comparison of vesicle based antigen delivery systems for delivery of hepatitis B surface antigen. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[9]  J. Bystryn,et al.  Enhanced Immunogenicity of Plasmodium falciparum Peptide Vaccines Using a Topical Adjuvant Containing a Potent Synthetic Toll-Like Receptor 7 Agonist, Imiquimod , 2008, Infection and Immunity.

[10]  P. Andersen,et al.  Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6'-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses. , 2005, Biochimica et biophysica acta.

[11]  B. Spiessens,et al.  Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: A pooled analysis of 11 clinical trials , 2009, Human vaccines.

[12]  P. Andersen,et al.  A Liposome-Based Mycobacterial Vaccine Induces Potent Adult and Neonatal Multifunctional T Cells through the Exquisite Targeting of Dendritic Cells , 2009, PloS one.

[13]  J. Schmidt,et al.  Vaccine adjuvant activity of 3M-052: an imidazoquinoline designed for local activity without systemic cytokine induction. , 2011, Vaccine.

[14]  蒋国强,et al.  Resiquimod , 2006 .

[15]  S. Akira,et al.  Regulation of dendritic cell function through toll-like receptors. , 2003, Current molecular medicine.

[16]  P. Toy,et al.  The Mitsunobu reaction: origin, mechanism, improvements, and applications. , 2007, Chemistry, an Asian journal.

[17]  Michael H. Smith,et al.  Randomized, Single-Blind, Placebo-Controlled Study of Topical Application of the Immune Response Modulator Resiquimod in Healthy Adults , 2003, Antimicrobial Agents and Chemotherapy.

[18]  P. Andersen,et al.  A Novel Liposome-Based Adjuvant CAF01 for Induction of CD8+ Cytotoxic T-Lymphocytes (CTL) to HIV-1 Minimal CTL Peptides in HLA-A*0201 Transgenic Mice , 2009, PloS one.

[19]  A. Bangham,et al.  Diffusion of univalent ions across the lamellae of swollen phospholipids. , 1965, Journal of molecular biology.

[20]  Richard L. Miller,et al.  Resiquimod and other immune response modifiers as vaccine adjuvants , 2007, Expert review of vaccines.

[21]  P. Andersen,et al.  Combination of the Cationic Surfactant Dimethyl Dioctadecyl Ammonium Bromide and Synthetic Mycobacterial Cord Factor as an Efficient Adjuvant for Tuberculosis Subunit Vaccines , 2004, Infection and Immunity.

[22]  R. Koup,et al.  Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake , 2017, Science Translational Medicine.

[23]  F. Mancini,et al.  Novel adjuvant Alum-TLR7 significantly potentiates immune response to glycoconjugate vaccines , 2016, Scientific Reports.

[24]  J. Bystryn,et al.  Topical imiquimod is a potent adjuvant to a weakly-immunogenic protein prototype vaccine. , 2006, Vaccine.

[25]  A. Hill,et al.  Small Cationic DDA:TDB Liposomes as Protein Vaccine Adjuvants Obviate the Need for TLR Agonists in Inducing Cellular and Humoral Responses , 2012, PloS one.

[26]  S. Patil,et al.  Imidazoquinolines: Recent Developments in Anticancer Activity. , 2016, Mini reviews in medicinal chemistry.

[27]  M. Cooke,et al.  Rational design of small molecules as vaccine adjuvants , 2014, Science Translational Medicine.

[28]  L. Cosmi,et al.  The novel synthetic immune response modifier R-848 (Resiquimod) shifts human allergen-specific CD4+ TH2 lymphocytes into IFN-gamma-producing cells. , 2003, The Journal of allergy and clinical immunology.

[29]  Michael Y. Gerner,et al.  In vivo characterization of the physicochemical properties of TLR agonist delivery that enhance vaccine immunogenicity , 2015, Nature Biotechnology.

[30]  K. Ishii,et al.  Sterically Stabilized Cationic Liposomes Improve the Uptake and Immunostimulatory Activity of CpG Oligonucleotides1 , 2001, The Journal of Immunology.

[31]  E. Balaraman,et al.  Mitsunobu and related reactions: advances and applications. , 2009, Chemical reviews.

[32]  S. Reed,et al.  Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approach , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[33]  Daniel E. Zak,et al.  Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPs. , 2017, Blood advances.

[34]  O. Mitsunobu,et al.  Preparation of Esters of Carboxylic and Phosphoric Acid via Quaternary Phosphonium Salts , 1967 .

[35]  R. Miller,et al.  Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod. , 1999, Cellular immunology.

[36]  L. French,et al.  Resiquimod, a topical drug for viral skin lesions and skin cancer , 2013, Expert opinion on investigational drugs.

[37]  N L Tilney,et al.  Patterns of lymphatic drainage in the adult laboratory rat. , 1971, Journal of anatomy.

[38]  M. Smith,et al.  Adjuvant activities of immune response modifier R-848: comparison with CpG ODN. , 2000, Cellular immunology.

[39]  Shiyin Yao,et al.  Enhancement of the Immunostimulatory Activity of a TLR7 Ligand by Conjugation to Polysaccharides. , 2015, Bioconjugate chemistry.

[40]  M. Reiter,et al.  The Immune Response Modifier and Toll-Like Receptor 7 Agonist S-27609 Selectively Induces IL-12 and TNF-α Production in CD11c+CD11b+CD8− Dendritic Cells 1 , 2003, The Journal of Immunology.

[41]  John P. Vasilakos,et al.  Cutting Edge: Activation of Murine TLR8 by a Combination of Imidazoquinoline Immune Response Modifiers and PolyT Oligodeoxynucleotides , 2006, The Journal of Immunology.

[42]  Bushra Zaidi,et al.  TLR7 imidazoquinoline ligand 3M-019 is a potent adjuvant for pure protein prototype vaccines , 2007, Cancer Immunology, Immunotherapy.

[43]  S. Reed,et al.  A nanoliposome delivery system to synergistically trigger TLR4 AND TLR7 , 2014, Journal of Nanobiotechnology.

[44]  S. Akira,et al.  Direct recognition of the mycobacterial glycolipid, trehalose dimycolate, by C-type lectin Mincle , 2009, The Journal of experimental medicine.

[45]  C. Yunis,et al.  First in Human Phase I Trial of 852A, a Novel Systemic Toll-like Receptor 7 Agonist, to Activate Innate Immune Responses in Patients with Advanced Cancer , 2007, Clinical Cancer Research.

[46]  P. Andersen,et al.  Inducing Dose Sparing with Inactivated Polio Virus Formulated in Adjuvant CAF01 , 2014, PloS one.

[47]  Yvonne Perrie,et al.  Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[48]  C. J. Martel,et al.  CAF01 Potentiates Immune Responses and Efficacy of an Inactivated Influenza Vaccine in Ferrets , 2011, PloS one.

[49]  P. Andersen,et al.  Liposome delivery of Chlamydia muridarum major outer membrane protein primes a Th1 response that protects against genital chlamydial infection in a mouse model. , 2008, The Journal of infectious diseases.

[50]  Mario Roederer,et al.  Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates , 2006, The Journal of experimental medicine.

[51]  Succinylation , 2020, Definitions.

[52]  T. Ottenhoff,et al.  A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human. , 2014, Vaccine.

[53]  Kelly J. Hitchens,et al.  Cutting Edge: Mincle Is Essential for Recognition and Adjuvanticity of the Mycobacterial Cord Factor and its Synthetic Analog Trehalose-Dibehenate , 2010, The Journal of Immunology.

[54]  O. Mitsunobu,et al.  Preparation of Esters of Phosphoric Acid by the Reaction of Trivalent Phosphorus Compounds with Diethyl Azodicarboxylate in the Presence of Alcohols , 1967 .

[55]  M. Pizza,et al.  Addition of a TLR7 agonist to an acellular pertussis vaccine enhances Th1 and Th17 responses and protective immunity in a mouse model. , 2017, Vaccine.

[56]  O. Levy,et al.  TLR7/8 adjuvant overcomes newborn hyporesponsiveness to pneumococcal conjugate vaccine at birth. , 2017, JCI insight.

[57]  J. Pedraz,et al.  Topical resiquimod: a promising adjuvant for vaccine development? , 2010, Expert review of vaccines.

[58]  J. St-Jean,et al.  Evaluation of novel synthetic TLR7/8 agonists as vaccine adjuvants. , 2016, Vaccine.

[59]  S. Reed,et al.  Age-Specific Adjuvant Synergy: Dual TLR7/8 and Mincle Activation of Human Newborn Dendritic Cells Enables Th1 Polarization , 2016, The Journal of Immunology.

[60]  J. Cross,et al.  Topical resiquimod promotes priming of CTL to parenteral antigens. , 2009, Vaccine.

[61]  B. Graham,et al.  TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity. , 2009, Vaccine.

[62]  P. Lambert,et al.  Synchronization of Dendritic Cell Activation and Antigen Exposure Is Required for the Induction of Th1/Th17 Responses , 2012, The Journal of Immunology.

[63]  H. M. Nielsen,et al.  Immunity by formulation design: induction of high CD8+ T-cell responses by poly(I:C) incorporated into the CAF01 adjuvant via a double emulsion method. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[64]  Y. Perrie,et al.  Comparison of the depot effect and immunogenicity of liposomes based on dimethyldioctadecylammonium (DDA), 3β-[N-(N',N'-Dimethylaminoethane)carbomyl] cholesterol (DC-Chol), and 1,2-Dioleoyl-3-trimethylammonium propane (DOTAP): prolonged liposome retention mediates stronger Th1 responses. , 2011, Molecular pharmaceutics.

[65]  Yvonne Perrie,et al.  Liposomal cationic charge and antigen adsorption are important properties for the efficient deposition of antigen at the injection site and ability of the vaccine to induce a CMI response. , 2010, Journal of controlled release : official journal of the Controlled Release Society.